Using RNA to interfere with a gene’s expression of disease-causing proteins is a validated therapeutic approach, but so far, the products in this drug class only address liver proteins. Reducing ...

Through its innovative asymmetric siRNA platforms, OliX Pharmaceuticals is opening up huge opportunities in RNA interference-therapeutic development to address unmet needs for various indications ...

It was not until 2018 that the US FDA approved the first therapy developed using the technique. Since then, there’s been a steady, but slow, number of RNAi treatments coming into the market. The ROBO ...

In drug discovery, very little of what’s learned from one project can typically be carried over to the next. “For every new target you go after with a small molecule, you basically start from scratch, ...

RNA interference (RNAi) therapeutics have garnered significant attention in clinical research due to their potential for treating various diseases, including genetic disorders, viral infections and ...

With six drugs approved for commercial development, Cambridge-based drugmaker Alnylam Pharmaceuticals Inc. is investing $250 million into its biomanufacturing plant in Norton.

- Company hosting an obesity/metabolic R&D webinar today, August 14, 2024, at 2:00 pm ET as Part IV of the 2024 Summer Series of R&D Webinars PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead ...

Alnylam's $250 million investment will enhance its Norton, Massachusetts facility with an enzymatic ligation platform to meet ...

Alnylam Pharmaceuticals is to invest $250m to expand its facility in Massachusetts, US, to meet the growing demand for RNAi ...

PHILADELPHIA, PA—Zilebesiran (Alnylam), an investigational therapeutic agent that interferes with messenger RNA to stop the production of angiotensinogen (AGT), lowers systolic blood pressure levels ...

PeptiDream Inc. recently announced that its second oral peptide therapeutic program, a dual IL-17A and IL-17F macrocyclic inhibitor for autoimmune diseases, has entered its clinical development ...